Inhibitory effects of endogenous L-arginine analogues on nitric oxide synthesis in platelets: Role in platelet hyperaggregability in hypertension

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 12, 2007, Pages 1267-1271

  De Meirelles, Luisa R ^a   Mendes Ribeiro, Antônio C ^a,b   Santoro, Marcelle M ^a   Mendes, Michely A P ^a   Da Silva, Michele N S B ^a   Mann, Giovanni E ^c   Brunini, Tatiana M C ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Asymmetric dimethylarginine; Hypertension; NG monomethyl L arginine; Nitric oxide; Platelets

Indexed keywords

AMINOGUANIDINE; ARGININE DERIVATIVE; C REACTIVE PROTEIN; COLLAGEN; CYCLIC GMP; FIBRINOGEN; LEUCINE; N(G) METHYLARGININE; N(G) NITROARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ADULT; ARTICLE; BIOSYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; MALE; PROTEIN BLOOD LEVEL; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ARGININE; BLOOD PLATELETS; C-REACTIVE PROTEIN; CYCLIC GMP; FEMALE; FIBRINOGEN; HUMANS; HYPERTENSION; INTERLEUKIN-6; LEUCINE; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLATELET AGGREGATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35549008481     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04712.x     Document Type: Article

References (29)

1. Waybill MM, Waybill PN. A practical approach to hypertension in the 21st century. J. Vasc. Interv. Radiol. 2003 14 : 961 75.
2. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003-04 secondary prevention trials. Hypertens. Res. 2005 28 : 385 407.
3. Oparil SM, Zaman A, Calhoun DA. Pathogenesis of hypertension. Ann. Intern. Med. 2003 139 : 761 76.
4. Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br. J. Pharmacol. 2006 147 (Suppl. 1 S193 201.
5. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ. Res. 2001 88 : 756 62.
6. Mehta JL, Chen LY, Kone BC, Mehta P, Turner P. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J. Lab. Clin. Med. 1995 125 : 370 7.
7. Camilletti A, Moretti N, Giacchetti G et al. Decreased nitric oxide levels and increased calcium content in platelets of hypertensive patients. Am. J. Hypertens. 2001 14 : 382 6.
8. Moss MB, Brunini TM, Soares de Moura R et al. Diminished l-arginine bioavailability in hypertension. Clin. Sci. 2004 107 : 391 7.
9. Brunini TMC, Resende AC, Moss MB, Soares de Moura R, Mendes Ribeiro AC. l-Arginine availability as a pathological mechanism in essential hypertension, chronic renal and heart failure. Vasc. Dis. Prev. 2005 2 : 37 51.
10. +L as the high affinity transporter for l-arginine in human platelets. up-regulation of l-arginine influx in uraemia. Eur. J. Physiol. 1999 438 : 573 57.
11. +)L. Pflügers Arch. 2003 445 : 547 50.
12. Deves R, Boyd CA. Transporters for cationic amino acids in animal cells: discovery, structure, and function. Physiol. Rev. 1998 78 : 487 545.
13. +L. A candiate gene for lysinuric protein intolerance. J. Biol. Chem. 1998 273 : 32 437 45.
14. +L-type by heterodimers of 4F2hc/CD98 and members of the glycoprotein-associated amino acid transporter family. EMBO J. 1999 18 : 49 57.
15. Boger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the 'l-arginine paradox' and acts as a novel cardiovascular risk factor. J. Nutr. 2004 134 (Suppl. 10 S2842 7.
16. Perticone F, Sciacqua A, Maio R et al. Asymmetric dimethylarginine, l-arginine, and endothelial dysfunction in essential hypertension. J. Am. Coll. Cardiol. 2005 246 : 518 23.
17. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005 352 : 1685 95.
18. Korhonen R, Lahti A, Kankaanranta H, Moilanen E. Nitric oxide production and signaling in inflammation. Curr. Drug. Targets Inflamm. Allergy 2005 4 : 471 9.
19. Cottone S, Vadala A, Vella MC, Mule G, Contorno A, Cerasola G. Comparison of tumour necrosis factor and endothelin-1 between essential and renal hypertensive patients. J. Hum. Hypertens. 1998 12 : 351 4.
20. Lechi C, Gaino S, Zuliani V et al. Elevated plasma fibrinogen levels in patients with essential hypertension are related to vascular complications. Int. Angiol. 2003 22 : 72 8.
21. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003 290 : 932 40.
22. Garanty-Bogacka B, Syrenicz M, Syrenicz A, Gebala A, Lulka D, Walczak M. Serum markers of inflammation and endothelial activation in children with obesity-related hypertension. Neuroendocrinol. Lett. 2005 26 : 242 6.
23. Brunini TMC, Moss MB, Siqueira MAS et al. Inhibition of l-arginine transport in platelets by asymmetric dimethylarginine and N-monomethyl-l- arginine: effects of arterial hypertension. Clin. Exp. Pharmacol. Physiol. 2004 31 : 738 40.
24. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003 42 : 1206 52.
25. Van der Bom JG, de Maat MP, Bots ML et al. Elevated plasma fibrinogen: Cause or consequence of cardiovascular disease? Arterioscler. Thromb. Vasc. Biol. 1998 18 : 621 5.
26. Chen LY, Mehta JL. Variable effects of l-arginine analogs on l-arginine-nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms. J. Pharmacol. Exp. Ther. 1996 276 : 253 7.
27. Haszon I, Papp F, Kovacs J et al. Platelet aggregation, blood viscosity and serum lipids in hypertensive and obese children. Eur. J. Pediatr. 2003 162 : 385 90.
28. Peeters AC, Netea MG, Janssen MC, Kullberg BJ, Van der Meer JW, Thien T. Pro-inflammatory cytokines in patients with essential hypertension. Eur. J. Clin. Invest. 2001 31 : 31 6.
29. Aronson D. Inflammatory markers: Linking unstable plaques to coronary event, an interventional perspective. Int. J. Cardiovasc. Intervent. 2004 6 : 110 18.